Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Holdings Raised by Rhumbline Advisers

Rhumbline Advisers boosted its stake in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) by 975.2% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 266,093 shares of the company’s stock after buying an additional 241,344 shares during the quarter. Rhumbline Advisers owned approximately 0.58% of Verrica Pharmaceuticals worth $186,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. State Street Corp raised its holdings in shares of Verrica Pharmaceuticals by 13.5% during the 3rd quarter. State Street Corp now owns 512,821 shares of the company’s stock valued at $744,000 after purchasing an additional 61,041 shares in the last quarter. Sovran Advisors LLC bought a new position in shares of Verrica Pharmaceuticals during the 4th quarter valued at $267,000. XTX Topco Ltd bought a new position in shares of Verrica Pharmaceuticals during the 3rd quarter valued at $335,000. Jane Street Group LLC raised its holdings in shares of Verrica Pharmaceuticals by 106.5% during the 3rd quarter. Jane Street Group LLC now owns 69,872 shares of the company’s stock valued at $101,000 after purchasing an additional 36,028 shares in the last quarter. Finally, Verition Fund Management LLC bought a new position in shares of Verrica Pharmaceuticals during the 3rd quarter valued at $89,000. Institutional investors own 42.45% of the company’s stock.

Analyst Ratings Changes

Separately, Needham & Company LLC restated a “hold” rating on shares of Verrica Pharmaceuticals in a report on Friday, December 20th. Four research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat.com, Verrica Pharmaceuticals has an average rating of “Hold” and an average price target of $9.50.

Verrica Pharmaceuticals Stock Up 4.8 %

Shares of VRCA stock opened at $0.64 on Tuesday. Verrica Pharmaceuticals Inc. has a 12-month low of $0.58 and a 12-month high of $11.41. The company has a market capitalization of $29.05 million, a P/E ratio of -0.35 and a beta of 1.44. The firm has a 50-day moving average price of $0.68 and a 200 day moving average price of $1.14.

Verrica Pharmaceuticals Profile

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.